Sharif [229] advocates for “vertical” therapeutic strategies that simultaneously target aqueous humor dynamics (e.g., via EP2 agonists like omidenepag isopropyl) and RGC survival pathways (e.g., BDNF gene therapy), addressing both the upstream and downstream pathology in glaucoma. This evidence concerns the gene BDNF and glaucoma.